• Molecular NameSpironolactone
  • SynonymNA
  • Weight416.582
  • Drugbank_IDDB00421
  • ACS_NO52-01-7
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.69
  • pkaN/A
  • LogD (pH=7, predicted)2.69
  • Solubility (experiment)0.0219 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-5.34
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds2
  • TPSA85.74
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA diuretic and is used as an antiandrogen.
  • Absorption_value73.0
  • Absorption (description)Fairly rapidly absorbed from the gastrointestinal tract. Food increases the bioavailability of unmetabolized spironolactone by almost 100%.
  • Caco_2N/A
  • Bioavailability25.0
  • Protein binding98.0
  • Volume of distribution (VD)10 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmSpironolactone (S) is extensively metabolized; it has three known active metabolites: canrenone (C), 7alpha-thiomethylspirononlactone (TS), and 6beta-hydroxy-7alpha-thiomethylspirononlactone (HTS).
  • Half life1.3 h
  • ExcretionUrine, bile
  • Urinary Excretion<1
  • Clerance93 ml/min/kg
  • ToxicityThe oral LD50 of spironolactone is greater than 1,000 mg/kg in mice, rats, and rabbits. Acute overdosage of spironolactone may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50>1,000 mg/kg